Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
447.50
-21.74 (-4.63%)
At close: Dec 18, 2024, 4:00 PM
392.51
-54.99 (-12.29%)
Pre-market: Dec 19, 2024, 7:31 AM EST
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B in the quarter ending September 30, 2024, with 11.61% growth. This brings the company's revenue in the last twelve months to $10.63B, up 10.06% year-over-year. In the year 2023, Vertex Pharmaceuticals had annual revenue of $9.87B with 10.51% growth.
Revenue (ttm)
$10.63B
Revenue Growth
+10.06%
P/S Ratio
10.87
Revenue / Employee
$1,967,741
Employees
5,400
Market Cap
115.24B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | 4.16B | 1.12B | 36.59% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elevance Health | 174.02B |
Pfizer | 59.38B |
Sanofi | 54.03B |
Bristol-Myers Squibb Company | 47.44B |
Medtronic | 33.00B |
Amgen | 32.53B |
Gilead Sciences | 28.30B |
Danaher | 23.74B |
VRTX News
- 7 days ago - Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy - Seeking Alpha
- 9 days ago - Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock - Benzinga
- 10 days ago - Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update - Business Wire
- 19 days ago - Undercovered Dozen: Arqit Quantum, CleanSpark, Sezzle, STAG Industrial + - Seeking Alpha
- 23 days ago - Vertex Pharma: Why I Am Buying This Dip - Seeking Alpha
- 4 weeks ago - Buy Signal Flashing For Struggling Biotech - Forbes
- 4 weeks ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript) - Seeking Alpha
- 4 weeks ago - Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript) - Seeking Alpha